Dr. Kumar on Understanding the Safety Profiles of Combination Therapies in Multiple Myeloma

Video

Shaji K. Kumar, MD, discusses the importance of understanding the safety profiles of combination therapies in multiple myeloma.

Shaji K. Kumar, MD, a consultant in the Division of Hematology and a professor of medicine with Mayo Clinic, discusses the importance of understanding the safety profiles of combination therapies in multiple myeloma.

When utilizing combination therapies in multiple myeloma, it’s critical to understand safety in addition to efficacy. Also, it’s of paramount importance to conduct detailed analyses that illustrate all quality-of-life factors. By doing so, patients can better understand the potential effects of certain therapies on their day-to-day lives, Kumar says.

In general, patients with newly diagnosed disease are recommended for triplet regimens, says Kumar. Although additional data are needed, more quadruplet regimens may be utilized in this setting. When treating patients with relapsed/refractory myeloma, it’s important to select the optimal therapy based on what the patient previously received, Kumar concludes.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD